Antiasthmatic Effect of Saxagliptin on Ovalbumin-Induced Allergic Asthma in Mice
In the current study, the protective activity of saxagliptin (SAX) on ovalbumin (OVA)-induced allergic asthma in mice was evaluated. Methods: Mice with OVA-induced allergic asthma were orally administered SAX at a dose of 10 mg/kg/day for 6 days. We determined the count of total cells, differential inflammatory cells and interleukin (IL)-13 concentration in bronchoalveolar lavage fluid (BAL). The concentration of lipid peroxidation marker, malondialdehyde (MDA), was also examined in lung homogenate. Histopathological alterations in lung tissues were also detected by Hematoxylin and Eosin staining. Results: SAX inhibited OVA-induced airway inflammation and oxidative stress in the lung. OVA-induced allergic asthma was suppressed by SAX as evidenced by decreased lung body weight ratio and leukocyte infiltration in the lungs, and also suppressed OVA-induced elevation of level of IL-13 in BAL. In addition, SAX decreased the MDA concentration in lung homogenate. Conclusion: Our study demonstrated that SAX attenuated OVA-induced allergic asthma and it may represent a promising agent for the control of allergic asthma.
Full Text Attachment